Your browser doesn't support javascript.
loading
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.
Okam, Maureen M; Esrick, Erica B; Mandell, Elyse; Campigotto, Federico; Neuberg, Donna S; Ebert, Benjamin L.
Afiliación
  • Okam MM; Division of Hematology, Brigham and Women's Hospital, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Esrick EB; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA.
  • Mandell E; Division of Hematology, Brigham and Women's Hospital, Boston, MA.
  • Campigotto F; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
  • Neuberg DS; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA.
  • Ebert BL; Division of Hematology, Brigham and Women's Hospital, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Blood ; 125(23): 3668-9, 2015 Jun 04.
Article en En | MEDLINE | ID: mdl-26045597
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Histona Desacetilasas / Ácidos Hidroxámicos / Anemia de Células Falciformes Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inhibidores de Histona Desacetilasas / Ácidos Hidroxámicos / Anemia de Células Falciformes Idioma: En Revista: Blood Año: 2015 Tipo del documento: Article